- Видео 16
- Просмотров 1 294
EUCOPE
Добавлен 3 фев 2021
EUCOPE is the trade association giving a bigger voice to small and mid-sized health technology companies in Europe
For more than a decade, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) has been the voice of small to mid-sized health technology companies in Europe. As a trade association, we advocate for sound public policy that supports innovation, while fostering a community built on a shared purpose: improving and saving the lives of European patients through innovative therapies and medical technology.
EUCOPE’s members - who represent over 2600+ innovative companies directly or via associations - are researching, designing, developing, supplying, manufacturing, and deploying the next generation of pharmaceutical innovation and therapeutic solutions around the continent.
For more than a decade, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) has been the voice of small to mid-sized health technology companies in Europe. As a trade association, we advocate for sound public policy that supports innovation, while fostering a community built on a shared purpose: improving and saving the lives of European patients through innovative therapies and medical technology.
EUCOPE’s members - who represent over 2600+ innovative companies directly or via associations - are researching, designing, developing, supplying, manufacturing, and deploying the next generation of pharmaceutical innovation and therapeutic solutions around the continent.
EUCOPE #LifeScienceLectures ep. 6: "Making CBHC for ATMPs in Rare Diseases a Reality"
EUCOPE hosted the sixth episode of Life Science Lectures on how to make cross-border healthcare (CBHC) for ATMPs reality for people living with a rare disease.
Our speakers stressed that CBHC is the only option for many patients, especially those living in smaller Member States. Thus, it is important to harmonise existing legislations to improve how it functions. We need timely leadership from the European Commission and national authorities, to work together with healthcare communities and find proper solutions, also through existing tools.
Our speakers stressed that CBHC is the only option for many patients, especially those living in smaller Member States. Thus, it is important to harmonise existing legislations to improve how it functions. We need timely leadership from the European Commission and national authorities, to work together with healthcare communities and find proper solutions, also through existing tools.
Просмотров: 37
Видео
EUCOPE #LifeScienceLectures Ep. 5 "The new EU HTA procedure: How can JCAs support access to OMPs
Просмотров 24Месяц назад
EUCOPE hosted the fifth episode of Life Science Lectures on the new EU HTA procedure, and how JCAs can support access to OMPs for people living with a Rare Disease. Moderated by our Alexander Natz, our speakers stressed the need to be flexible in the methodology for OMPs, taking into account the specificities of rare and ultra-rare diseases. Using adequate information will avoid biased discussi...
EUCOPE's #LifeScienceLectures - Episode Four "Leveraging early advice opportunities in EU HTA"
Просмотров 2887 месяцев назад
On the fourth episode, we discuss how best to navigate early advice opportunities with the new EU health technology assessment (HTA), which will be mandatory for all new oncology products and ATMPs from 12 January 2025.
EUCOPE's #LifeScienceLectures - Episode Three "EU HTA Regulation"
Просмотров 11410 месяцев назад
On the third episode, we will talk about the interactions between the EU Health Technology Assessment (#HTA) Regulation and the Pharmaceutical Package. The (EU) Regulation 2021/2282 on health technology assessment (HTA) and the revision of the #pharmaceutical manufacturing legislation will play a key role in patients’ access to innovative therapies in the coming decades. While the two legal ref...
EUCOPE's #LifeScienceLectures - Episode Two "Defining High Unmet Medical Need (HUMN)"
Просмотров 56Год назад
EUCOPE's Life Science Lectures - Episode Two "Defining High Unmet Medical Need: Will it steer innovation towards filling existing gaps" 📅7 July 2023 The revised pharmaceutical framework includes a definition of UMN and HUMN, which aims at steering innovation toward therapeutic areas with existing gaps, especially in #rarediseases. For the second episode in our Life Science Lectures #webinar ser...
EUCOPE's Life Science Lectures - Episode One "Attaching Conditionalities to Incentives"
Просмотров 55Год назад
On 30 May, EUCOPE - the European Confederation of Pharmaceutical Entrepreneurs hosted the inaugural episode of the Life Science Lectures webinar series titled “Attaching conditionalities to incentives: the right path to improve access?” Episode One delved into the incentive system outlined in the EU Pharmaceutical Package, with the aim to shed light on how these provisions could impact innovati...
WEBINAR: How recent legislative changes impact the German P&R landscape
Просмотров 290Год назад
The statutory health insurance financial stabilization act, approved by German Parliament last November, made substantial changes to the characteristics of pricing and reimbursement in Europe’s largest pharmaceutical market. For instance, the new law reduces the free pricing period from 12 to 6 months and changes the guard rails of the additional benefit assessment determining price anchors for...
EUCOPE Partnerships in Focus - Sheela Upadhyaya, FIPRA / Together4RareDiseases
Просмотров 332 года назад
At EUCOPE, our commitment is to lead and engage in #partnerships spanning the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve, and #healthcare systems overall. Our Partnerships in Focus series highlights different associates that we partner with to co-create solutions to various challenges across the healthcare ecosystem related to #healt...
Webinar: "The Future of Rare Diseases in Europe & Czech Republic"
Просмотров 662 года назад
This special webinar gives an insight into the ways the #European framework on #rarediseases paves the way forward and complements actions at the national level. We hold this debate with representatives of the #CzechRepublic that will hold the rotating presidency of the Council from July 2022 to December 2022. 🔑The event focuses on how the debate regarding fostering innovation and patient acces...
EUCOPE Partnerships in Focus - Maciej Gajewski, Alexion-AstraZeneca
Просмотров 432 года назад
At EUCOPE, our commitment is to lead and engage in #partnerships spanning the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve and #healthcare systems overall. Our Partnerships in Focus series highlights different associates that we partner with to co-create solutions to various challenges across the healthcare ecosystem related to #health...
EUCOPE Partnerships in Focus - Toon Digneffe, Takeda
Просмотров 502 года назад
At EUCOPE, our commitment is to lead and engage in partnerships spanning across the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve and healthcare systems overall. Our Partnerships in Focus series highlights different associates that we partner with to co-create solutions to various challenges across the #healthcare ecosystem related to h...
Pulling out all the stops to deliver high-quality care for European cancer patients
Просмотров 422 года назад
Pulling out all the stops to deliver high-quality care for European cancer patients
The Future of Rare Diseases in Sweden & Denmark
Просмотров 802 года назад
EUCOPE and IML webinar on the impact, challenges and opportunities of the OMP Regulation review for the rare disease community in Denmark and Sweden along with a panel of EU and national stakeholders.
Table ronde: L' avenir des maladies rares
Просмотров 543 года назад
EUCOPE, in partnership with FranceBiotech, hosted a roundtable on the revision of the orphan medicine and paediatric regulations with French stakeholders on 30 June. The orphan and paediatric legislation has considerably accelerated research efforts over the last two decades and has contributed to the development of more than 190 treatments in the field of rare diseases. The revision of the leg...
EUCOPE - BIO Webinar: The EU and US Biotech Sector’s Response to COVID-19
Просмотров 113 года назад
On 24 September 2020, EUCOPE, together with BIO, hosted a webinar focusing on the response of the global biotech sector to COVID-19 pandemic as well as measures taken by regulatory and policy institutions in the EU and US. The objective of the webinar was to understand the reaction of the two jurisdictions to the pandemic.
🌷 "Promo sm"